| | Proteomic analysis of heart disease: from molecular mechanism to biomarker development
Our laboratory undertakes the study of the protein complement, or proteome, of cells, tissues or body fluids to understand the complex regulation and control that change with disease. This allows us to discover novel changes to the proteome that underpin the molecular mechanisms that drive disease. Furthermore, discovery of new potential biomarkers that are altered in plasma during disease onset and development allows us to create new diagnostics and prognostic tests for clinical use. |
| | Major funding sources
10/01/02 - 9/30/2009
Title: Proteomics of Adaptation to Ischemia/Hypoxia in Heart, Lung and Blood, IH N01-HV-28180, Funding agency: NIH/NHLBI
Contract 8/1/2004-6/30/2009
Title: Pathobiology of Cardiac Dyssynchrony and Resynchronization P01 HL77180-01 Funding agency: NIH/NHLBI
PPG 4/1/2005-3/31/2010
Title: Mitochondrial Function in Ischemic Heart Disease P01-HL081427-02 Funding agency: NIH/NHLBI
PPG 01/01/07 - 12/31/12
Title: Pulmonary Vascular Disease: translational to clinic P50 HL 084946-01 Funding agency: NIH/NHLBI SCCOR Industry Partnerships with
Unpath Inc
Varian Ludesi Inc.
Beckman Coulter
Applied Biosystems Inc |
| | Examples of Collaborations within JHU Cardiology and Pediatrics
Gordon Tomaselli, MD
David Kass, MD
Brian O'Rourke, MD
Eduardo Marban, MD
Joao Lima, MD
Hal Dietz, MD
Anne Murphy, MD
Allen Everett, MD |
| | Books Edited
Van Eyk JE, Dunn M, editors. Genomic and Proteomic Analysis of Cardiovascular Disease: molecular mechanism, therapeutic targets and diagnostics. Wiley and Son Inc., January 2003
Van Eyk JE, Dunn M., editors. Clinical Proteomics: from diagnosis to therapy. Wiley and Son Inc., Spring 2007
Reviews and Book Chapters
Stanley BA, Van Eyk JE. Clinical Proteomics - Technologies to define and diagnose heart disease in Molecular Mechanisms of Cardiac Hypertrophy and Failure (ed Walsh R) 2005 pp 651-666.
Jaffe AS, Van Eyk JE. Troponin Fragments-Diagnostic potential in Cardiac Biomarkers in the management of cardiac disease. (ed. Morrow DA) Contemporary Cardiology series. 2006 pp 161-176.
Fu Q, Van Eyk JE, Proteomics and heart disease: Identifying biomarkers of clinical utility. Expert Rev. Proteomics 2006;3:237-49
Manuscripts (selected from over 100)
66. Arrell DK, Elliott ST, Kane LA, Guo Y, Ko YH, Pedersen PL, Robinson J, Murata M, Murphy AM, Marban E, Van Eyk JE. Proteomic Analysis of Pharmacological Preconditioning. Novel Protein Targets Converge to Mitochondrial Metabolism Pathways. Circ Res. 2006;99:5:706-14.
Ji Y, Neverova I, Van Eyk JE, Bennett BM. Nitration of tyrosine 92 mediates the activation of rat microsomal glutathione s-transferase by peroxynitrite. J Biol Chem. 2006;281:1986-91
McDonald T, Sheng S, Stanley F, Chen D, Ko Y, Cole RN, Pederson P, Van Eyk JE. Expanding the subproteome of the inner mitochondria using protein separation technologies: one and two-dimensional liquid chromatography and two-dimensional gel electrophoresis. Mol. Cell. Proteomics 2006;5:2392-411.
Gundry RL, Fu Q, Jelinek CA, Van Eyk JE, Cotter RJ. Investigation of an albumin-enriched fraction of human serum and its albuminone. Proteomics: clinical applications 2007 (in press) |
